Profit Investment Management LLC Has $4.31 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Profit Investment Management LLC lowered its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 32.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 68,001 shares of the biotechnology company’s stock after selling 32,222 shares during the period. Viking Therapeutics comprises approximately 3.4% of Profit Investment Management LLC’s holdings, making the stock its largest position. Profit Investment Management LLC owned 0.06% of Viking Therapeutics worth $4,305,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of VKTX. Vanguard Group Inc. lifted its stake in Viking Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 5,381,904 shares of the biotechnology company’s stock worth $100,157,000 after purchasing an additional 97,552 shares in the last quarter. CWM LLC lifted its stake in Viking Therapeutics by 70.6% in the 2nd quarter. CWM LLC now owns 1,518 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 628 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in Viking Therapeutics by 721.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 180,000 shares of the biotechnology company’s stock worth $11,396,000 after purchasing an additional 158,100 shares in the last quarter. Commonwealth Equity Services LLC purchased a new stake in Viking Therapeutics in the 1st quarter worth $1,422,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in Viking Therapeutics in the 2nd quarter worth $5,036,000. Institutional investors own 76.03% of the company’s stock.

Insider Activity

In other news, CEO Brian Lian sold 115,859 shares of Viking Therapeutics stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $57.58, for a total value of $6,671,161.22. Following the sale, the chief executive officer now owns 2,354,927 shares in the company, valued at $135,596,696.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director J Matthew Singleton sold 20,786 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.53, for a total transaction of $1,195,818.58. Following the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $546,535. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Brian Lian sold 115,859 shares of the business’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $57.58, for a total transaction of $6,671,161.22. Following the transaction, the chief executive officer now owns 2,354,927 shares in the company, valued at $135,596,696.66. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 516,671 shares of company stock worth $33,810,813 over the last 90 days. 4.70% of the stock is currently owned by company insiders.

Viking Therapeutics Trading Up 2.6 %

Shares of Viking Therapeutics stock traded up $1.64 during trading on Friday, hitting $64.09. 641,614 shares of the company’s stock were exchanged, compared to its average volume of 4,373,831. The business has a 50-day simple moving average of $61.22 and a 200-day simple moving average of $62.64. Viking Therapeutics, Inc. has a 52-week low of $8.28 and a 52-week high of $99.41.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.06. During the same quarter last year, the business posted ($0.19) EPS. Equities research analysts predict that Viking Therapeutics, Inc. will post -1 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on VKTX shares. Raymond James upped their target price on shares of Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. started coverage on shares of Viking Therapeutics in a research report on Wednesday, September 11th. They set an “overweight” rating and a $80.00 target price on the stock. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research report on Tuesday, September 24th. Oppenheimer restated an “outperform” rating and set a $138.00 target price on shares of Viking Therapeutics in a research report on Wednesday, September 25th. Finally, Morgan Stanley restated an “overweight” rating and set a $105.00 target price on shares of Viking Therapeutics in a research report on Thursday, September 12th. One analyst has rated the stock with a sell rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Viking Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $108.60.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.